Long COVID 12 months after discharge: persistent symptoms in patients hospitalised due to COVID-19 and patients hospitalised due to other causes-a multicentre cohort study

Long-term-specific sequelae or persistent symptoms (SPS) after hospitalisation due to COVID-19 are not known. The aim of this study was to explore the presence of SPS 12 months after discharge in survivors hospitalised due to COVID-19 and compare it with survivors hospitalised due to other causes. P...

Full description

Saved in:
Bibliographic Details
Published in:BMC medicine 2022-02, Vol.20 (1), p.92-92, Article 92
Main Authors: Rivera-Izquierdo, Mario, Láinez-Ramos-Bossini, Antonio Jesús, de Alba, Inmaculada Guerrero-Fernández, Ortiz-González-Serna, Rocío, Serrano-Ortiz, Álvaro, Fernández-Martínez, Nicolás Francisco, Ruiz-Montero, Rafael, Cervilla, Jorge A
Format: Article
Language:English
Subjects:
Adult
Cohort Studies
Cohort study
Comparative analysis
COVID-19 - complications
Follow-up
Hospital care
Hospitalization
Humans
Long term
Patient Discharge
Patient outcomes
Persistent COVID-19
Prospective Studies
SARS-CoV-2
Sequelae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Long-term-specific sequelae or persistent symptoms (SPS) after hospitalisation due to COVID-19 are not known. The aim of this study was to explore the presence of SPS 12 months after discharge in survivors hospitalised due to COVID-19 and compare it with survivors hospitalised due to other causes. Prospective cohort study, the Andalusian Cohort of Hospitalised patients for COVID-19 (ANCOHVID study), conducted in 4 hospitals and 29 primary care centres in Andalusia, Spain. The sample was composed of 906 adult patients; 453 patients hospitalised due to COVID-19 (exposed) and 453 hospitalised due to other causes (non-exposed) from March 1 to April 15, 2020, and discharged alive. The main outcomes were (1) the prevalence of SPS at 12 months after discharge and (2) the incidence of SPS after discharge. Outcome data at 12 months were compared between the exposed and non-exposed cohorts. Risk ratios were calculated, and bivariate analyses were performed. A total of 163 (36.1%) and 160 (35.3%) patients of the exposed and non-exposed cohorts, respectively, showed at least one SPS at 12 months after discharge. The SPS with higher prevalence in the subgroup of patients hospitalised due to COVID-19 12 months after discharge were persistent pharyngeal symptoms (p
ISSN:1741-7015
1741-7015
DOI:10.1186/s12916-022-02292-6